US/UK/Canada

Share

Links

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.
Zofia Piotrowska, MD, lead author of the study
In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.
Zofia Piotrowska, MD
In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.
Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors
The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.
ASTRO President David C. Beyer, MD, FASTRO
Pick a time period -
Tags ( Active)

ASTRO applauds nominations of Tom Price and Seema Verma to top federal health posts

ARLINGTON, Va., November 29, 2016 – The American Society for Radiation Oncology (ASTRO) today expressed its support for the nominations of Tom Price, MD, as Health and Human Services (HHS) Department Secretary and Seema Verma as Centers for Medicare and Medicaid Services (CMS) Administrator. ASTRO Chair David C. Beyer, MD, FASTRO, issued the following statement: “ASTRO congratulates Dr. Tom Price on his nomination to serve as HHS Secretary. We believe Dr. Price's experience and expertise as a physician will be critical in addressing the health care challenges faced by patients and health

Radiation Oncology Institute announces winners of innovative research projects in radiation oncology awards

Projects examine how to better manage cancer patient outcomes using smartphone technology and fitness trackersARLINGTON, Va., October 13, 2016 – The Radiation Oncology Institute (ROI) has selected two promising, early career researchers to receive a total of nearly $100,000 for research on how physicians can use the real-time monitoring and feedback capability of smart technologies to improve outcomes for cancer patients. The two winners of ROI’s 2016 Innovative Projects in Radiation Oncology grant awards were recently recognized at the American Society for Radiation Oncology (ASTRO) 58th

Clinical trials and emerging research in radiation oncology to be featured at ASTRO’s Annual Meeting in Boston

Press program will highlight innovations in cancer care from 15 leading studies in five news briefings held live on-site and via webcastThe American Society for Radiation Oncology (ASTRO) announced today the press program for its 58th Annual Meeting, which includes multiple reports from phase III clinical trials, researchers from leading institutions in the U.S. and abroad, and examinations of a range of cancer types and patient populations. Researchers will share their findings in a series of briefings held on-site at the Boston Convention & Exhibition Center and webcast to registered

Radiation oncologists meet with members of Congress to advocate for sustained increases to cancer research funding

Nearly 100 ASTRO members also called on legislators to protect patient access to high quality cancer careWASHINGTON, D.C., May 25, 2016 – Radiation oncologists from across the United States convened on Capitol Hill yesterday to encourage members of Congress to invest in cancer research with sustainable and predictable funding and to protect patients’ access to high quality cancer care through value-based physician payment models. The 95 doctors were in Washington for approximately 150 meetings with Congressional leaders from their home districts and states as part of the American Society

Advances in Radiation Oncology journal closes first issue

Advances in Radiation Oncology, ASTRO’s new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy. “The American Society for Radiation Oncology (ASTRO) is, at its core, a society primed for innovation,” said founding editor Robert C. Miller, MD, MBA, of the Mayo Clinic in Florida and Rochester, Minnesota, in his inaugural editorial. “It

ASTRO commends proposed increases for cancer research support in President’s 2017 budget

Budget request includes $1 billion for Cancer Moonshot Initiative and 13 percent increase in biomedical research funding at the National Cancer InstituteThe American Society for Radiation Oncology (ASTRO) commends the proposed investment in cancer-related research announced in the Fiscal Year 2017 Budget  released yesterday by the White House. ASTRO, whose members include nearly all practicing radiation oncologists in the United States, further encourages policymakers to increase

Leading oncology research to be highlighted in news briefings at the 2016 Multidisciplinary Head and Neck Cancer Symposium

News briefings also available live via webcastWhat:  The 2016 Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS), will explore the heterogeneous group of tumors in head and neck cancers and the various complexities and factors in providing treatment. The multidisciplinary approach includes surgery, radiation therapy and chemotherapy in addition to novel molecular biologic therapies that show promise in improving patient outcomes.

ASTRO applauds and pledges support to President’s commitment to advancing cancer research and improving patient lives

American Society for Radiation Oncology chair ASTRO Chair Bruce D. Minsky, MD, FASTRO responds to President’s State of the Union call for progressThe American Society for Radiation Oncology (ASTRO) applauds President Obama and Vice President Biden for affirming their commitment to improving cancer patients’ lives through the “moonshot” effort in cancer research announced in the President’s State of the Union speech on Tuesday. ASTRO pledges its support of the initiative to bolster resources and foster collaboration among the oncology research community, as well as Vice President Biden’s

Anti-androgen therapy and salvage RT improves overall survival for a prostate cancer recurrence after a prostatectomy

10-year follow up of RTOG 9601 also shows lower incidence of prostate cancer-related death without increase of toxicityProstate cancer patients who face recurrence after radical prostatectomy (RP) have better overall survival rates with a combination of salvage radiation therapy (RT) and 24 months of anti-androgen therapy (AAT) than with RT alone, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting. Many men with prostate cancer who undergo RP—surgical removal of the prostate—experience recurrence, as evidenced by an

Cleveland Clinic nurse receives 2015 ASTRO Annual Meeting Nurses Abstract Award

The American Society for Radiation Oncology (ASTRO) has awarded the 2015 Annual Meeting Nurses Abstract Award to Bridgett Harr, CPN, Cleveland Clinic, Cleveland, for the abstract “Advanced Practice Nurse Follow-up Clinic Reduces Emergency Room Visits and Admissions in High-Risk Patients after Chemoradiation Therapy for Head and Neck Cancer.” The Annual Meeting Nurses Abstract Award honors the highest rated abstract with a nursing designation. Award candidates must be nurses who are the lead author or co-author of an abstract selected for presentation at the 2015 ASTRO Annual Meeting. Ms.

ASTRO awards $33,500 in individual grants to 41 researchers presenting at 2015 Annual Meeting

The American Society for Radiation Oncology (ASTRO) has selected 41 recipients to receive a total of $33,500 for the 2015 Annual Meeting Abstract Awards. The awardees will be recognized at ASTRO’s 57th Annual Meeting, October 18-21, 2015 at the Henry B. González Convention Center in San Antonio. “The excellent contribution by top radiation oncologist researchers to the field, as well as to ASTRO’s 57th Annual Meeting, has continued this year with more than 2,800 abstract submissions received,” said ASTRO President Bruce D. Minsky, MD, FASTRO. “These abstracts represent the important work

ASTRO’s 57th Annual Meeting in San Antonio to showcase more than 2,100 radiation oncology clinical trials from around the world

Five live, webcast news events highlight top studies and ASTRO initiativesFairfax, Va., September 1, 2015—The American Society for Radiation Oncology’s (ASTRO’s) 57th Annual Meeting will be held at the Henry B. González Convention Center, October 18-21, 2015. The event is the nation’s premier scientific gathering in radiation oncology, and the results of more than 2,100 radiation oncology-specific research studies and clinical trials conducted around the world will be presented at the four-day meeting. The 2015 Annual Meeting is expected to attract nearly 11,000 oncologists from all

Seven physician-researchers awarded a total of $675,000 in grants for radiation oncology research

Fairfax, Va., August 25, 2015—The American Society for Radiation Oncology (ASTRO) has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute (ROI) Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health

Seventeen ASTRO members awarded Fellows designation

The American Society for Radiation Oncology (ASTRO) has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ASTRO’s 57th Annual Meeting on Tuesday, October 20 at the Henry B. Gonzalez Convention Center in San Antonio. ASTRO Fellows designation, or FASTRO, honors those that have been an Active or Emeritus member of ASTRO for at least 15 years, given the equivalent of 10 years of service to ASTRO and significantly added to the field of radiation oncology in the areas of research,

Leading surgeon, researcher Jack A. Roth, MD, named 2015 ASTRO Honorary Member

The American Society for Radiation Oncology (ASTRO) has selected leading surgeon and researcher Jack A. Roth, MD, as the 2015 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. Dr. Roth will be inducted as the 2015 ASTRO Honorary Member during the Awards Ceremony on Tuesday, October 20, at ASTRO’s 57th Annual Meeting, October 18-21, 2015, at the Henry B. Gonzalez Convention Center in San Antonio. The first ASTRO Honorary Membership was awarded in 1989.

Drs. Bogardus, Mansfield and Mitchell selected to receive 2015 ASTRO Gold Medal

Fairfax, Va., July 9, 2015 – The American Society for Radiation Oncology (ASTRO) has chosen three renowned radiation oncology physicians and researchers to receive the 2015 ASTRO Gold Medal: Carl R. Bogardus, Jr., MD, FASTRO, Carl M. Mansfield, MD, ScD (Hon.), FASTRO, and James B. Mitchell, PhD, FASTRO. Drs. Bogardus, Mansfield and Mitchell will be recognized with the ASTRO Gold Medal during the Awards Ceremony on Tuesday, October 20, 2015, at ASTRO’s 57th Annual Meeting, October 18-21, 2015 at the Henry B. González Convention Center in San Antonio. The ASTRO Gold Medal is the highest

Extended-field intensity modulated radiation therapy for cervical and endometrial cancers does not increase risk of duodenal toxicity

A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology (PRO), the American Society for Radiation Oncology’s (ASTRO’s) journal focused on the clinical practice of radiation oncology. IMRT is one of the radiation therapy (RT) treatment options for cervical and endometrial cancers. RT is employed to treat both known

ILROG issues treatment guidelines for pediatric Hodgkin lymphoma that incorporate advanced imaging techniques to minimize radiation dose

The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline that outlines the use of 3-D computed tomography (CT)-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects. The guideline will be published in the March-April issue of Practical Radiation Oncology (PRO), the clinical practice journal of the American Society for Radiation Oncology (ASTRO). Historically, pediatric Hodgkin lymphoma patients were

Improved survival for patients with brain metastases who are ≤50 years old and receive SRS alone, without whole brain RT

Affirms ASTRO’s 2014 Choosing Wisely® recommendation for SRSCancer patients with limited brain metastases (one to four tumors) who are ≤50 years old should receive stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT), according to a study available online, open-access, and published in the March 15, 2015 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). For patients ≤50 years old who received SRS alone, survival was improved by 13

Secondary analysis of RTOG 0247 demonstrates favorable overall survival rates for rectal cancer patients

Patients received two different chemotherapy regimens concurrently with radiation therapy prior to surgeryFairfax, Va., January 9, 2015 —Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation

Physician survey indicates positive experience and desire for more formal guidelines to improve the peer review process

Peer review is a common practice in medicine to support the complementary, multidisciplinary team approach in healthcare. A 2013 survey of radiation oncologists indicates that they would like more formal recommendations and guidance in order to improve the peer review process, according to a study published in the January-February 2015 issue of Practical Radiation Oncology (PRO), the clinical practice journal of the American Society for Radiation Oncology (ASTRO). The study, “Practice patterns for peer review in radiation oncology,” analyzed the results of a radiation oncology-specific,

Analysis shows increased use of hypofractionated whole-breast irradiation for patients with early-stage breast cancer

Treatment influenced by type of facility, patient’s travel distance to cancer centerFairfax, Va., December 9, 2014—The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology • Biology •

10 years of data reveals excellent, sustained local control with minimal side effects for medically inoperable, early stage lung cancer patients

Data from patients that received high-dose rate stereotactic body radiotherapyAnalysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The Symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media